Transforming a Traditional Biopharma R&D Campus Into a Modern CDMO – JOINN Biologics US

ISPE SF and CLSA Logos

Transforming a Traditional Biopharma R&D Campus  Into a Modern CDMO – JOINN Biologics US


In 1990 Berlex Biosciences bought the Ortho research center and turned it into their research headquarters. In 1992, they built the three-story, 73,000 sq/ft bioproduction facility, Building L. The R&D campus was unoccupied between 2008 and 2017 when it was bought by JOINN Labs. JOINN Biologics US was established as a new biologics CDMO occupying the bioproduction facility.

Today JOINN Biologics US is a combination of “Big Pharma” infrastructure and modern, flexible, contract manufacturing capabilities. JOINN Biologics has modernized the Cell Line Development, Process Development, Analytical and cGMP manufacturing capabilities to include Mass Spec, an ambr 250, recommissioned the multiple stainless steel bioreactors and installed multiple single use bioreactors.

Please join us as we discuss what it takes to modernize a facility to once again make cGMP biotherapeutics at the site.


Jon Gingrich, Vice President of Business Development, JOINN Biologics US


Instructions to join will be emailed one day prior

Program Managers:
Tate Chandler, Project Executive, XL Construction
Kandice Lee, Science + Technology Sector Development Lead | Account Manager, Stantec

Graphics by:
Savanna Beebee, Project Coordinator, Dome Construction

Social Media by:
Jason Roth, Senior Associate Business Developer, HGA


ISPE SF 8-19-20 Info Graphic

ISPE SF 8-19-20 Info Graphic 2